Risk of Fracture With Dipeptidyl Peptidase-4 Inhibitors, Glucagon-like Peptide-1 Receptor Agonists, or Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Network Meta-analysis Combining 177 Randomized Controlled Trials With a Median Follow-Up of 26 weeks

Aim: This study aims to investigate the association between the use of dipeptidyl peptidase-4 inhibitors (DPP-4i), glucagon-like peptide-1 receptor agonists (GLP-1 RAs), or sodium-glucose cotransporter-2 inhibitors (SGLT-2i) and the risk of fracture among patients with type 2 diabetes mellitus. Meth...

Descripción completa

Detalles Bibliográficos
Autores principales: Chai, Sanbao, Liu, Fengqi, Yang, Zhirong, Yu, Shuqing, Liu, Zuoxiang, Yang, Qingqing, Sun, Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9285982/
https://www.ncbi.nlm.nih.gov/pubmed/35847027
http://dx.doi.org/10.3389/fphar.2022.825417

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9285982/
https://www.ncbi.nlm.nih.gov/pubmed/35847027
http://dx.doi.org/10.3389/fphar.2022.825417

Ejemplares similares